Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Enas Sallam

Internal Medicine Sarasota, FL Medical Doctor

NPI 1578553434 CMS profile 206829

5350 University Pkwy, Suite 101, Sarasota, FL 34243

Open in the dashboard

General payments

$6,985

373 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Enas Sallam of Sarasota, FL is reported in the CMS Open Payments database as having received $6,985 across 373 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,918 76
2024 General $1,346 61
2023 General $648 32
2022 General $935 53
2021 General $755 50
2020 General $718 50
2019 General $666 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Enas Sallam
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Enas Sallam were reported at $1,918. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Enas Sallam Internal Medicine median Middle half National median
2019 $666 $159 $48–$570 $163
2020 $718 $119 $33–$402 $114
2021 $755 $135 $37–$521 $132
2022 $935 $141 $42–$496 $149
2023 $648 $149 $45–$519 $160
2024 $1,346 $154 $47–$537 $164
2025 $1,918 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $830 48 payments
  2. Pfizer Inc. $818 53 payments
  3. AbbVie, Inc. $796 39 payments
  4. Lilly USA, LLC $458 25 payments
  5. Amgen Inc. $430 28 payments
  6. GlaxoSmithKline, LLC. $337 20 payments
  7. Merck Sharp & Dohme Corporation $297 17 payments
  8. Novartis Pharmaceuticals Corporation $248 11 payments
  9. Exact Sciences Corporation $227 8 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $220 17 payments
  11. Other $2,325 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,879 371 payments
  2. Education $106 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $663 40 payments
  2. RYBELSUS $554 31 payments
  3. ELIQUIS $318 22 payments
  4. Repatha $306 20 payments
  5. TRELEGY ELLIPTA $262 15 payments
  6. UBRELVY $258 14 payments
  7. VRAYLAR $252 11 payments
  8. Kerendia $217 10 payments
  9. VERQUVO $216 10 payments
  10. LEQVIO $209 8 payments
  11. Other $6,457 363 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

4,564

Median for Internal Medicine: 777

Drug cost

$179,920

Median for Internal Medicine: $73,373

Branded share of claims

12.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 33 $33,390
Jardiance Empagliflozin Brand 11 $18,275
Mounjaro Tirzepatide Brand 15 $16,102
Xarelto Rivaroxaban Brand 11 $13,037
Januvia Sitagliptin Phosphate Brand 13 $12,228
Premarin Estrogens, Conjugated Brand 13 $6,227
Synthroid Levothyroxine Sodium Brand 50 $5,120
Rosuvastatin Calcium Generic 345 $4,127
Estradiol Generic 58 $4,060
Yuvafem Estradiol Brand 16 $3,513

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$126,686

Of which drugs: $586

Medicare patients

492

Average age 77

Services billed

2,667

369 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 31%
Osteoporosis 29%
Depression 25%
Atrial fibrillation 18%
Cancer 18%
Diabetes 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 1,120 $101

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $97
$97 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $50
  • Lundbeck LLC $27
$77 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $75
$75 — —
ELIQUIS
  • PFIZER INC. $71
$71 33 —
Veozah
  • Astellas Pharma US Inc $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record